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Abstract: Neoadjuvant chemoradiotherapy for resectable oesophageal cancer improves
overall survival compared to surgery alone but is associated with increased toxicity.
NeoSCOPE is a trial of two different nCRT regimens for resectable oesophageal and was the
first multi-centre trial in the UK to incorporate 4D-CT into the radiotherapy planning. Using
NeoSCOPE 4D-CT cases, we undertook a dosimetric comparison study of 3D-CT versus 4D-CT
plans comparing target volume coverage and dose to organs at risk. We used established
normal tissue complication probability (NTCP) models to evaluate the potential toxicity
reduction of using 4D-CT plans in oesophageal cancer. Our work shows that incorporating
4D-CT into treatment planning may significantly reduce the toxicity burden from this
treatment.
Introduction
Despite improvements in surgical techniques, outcomes from surgery for oesophageal
cancer (OC) remain poor [1]. Neoadjuvant chemoradiotherapy (nCRT) is a treatment
strategy that has been shown to improve outcomes, but is associated with concerns over
toxicity, particularly in the post-operative setting [2]. This is in part responsible for the
variable uptake of nCRT around the UK [3, 4].
Limiting dose to organs at risk (OARs) is postulated to reduce post-operative complications
but traditionally decisions were based on dose volume histograms, in turn based on a 3D
scan, which is a snapshot in time of both the tumour position, but also of OARs. Respiration
(leading to tumour deformation and motion particularly in the cranio-caudal direction),
swallowing, peristalsis, gastric filling, emptying and vascular/cardiac pulsations all effect the
position of the tumour during treatment [5-7] and can affect the doses received by the
OARs.  
Two methods currently in use accounting for this motion are respiratory gating and four-
dimensional CT (4D-CT) planning. The use of 4D-CT scanning has the potential to reduce the
resulting risk of geographical miss, by accounting for this patient-specific variation over the
course of a respiration cycle.[7] The NeoSCOPE Trial was the first multi-centre UK trial to
incorporate 4D-CT into RT planning. [8]
In addition to characterising the range of motion, 4D-CT has been shown to have a
dosimetric benefit in non-small cell lung cancer with Cole et al. showing that by reducing
dose to OARs, 4D-CT allowed isotoxic dose escalation, with the hope that this would lead to
improved local control and better overall survival. [5] It is not known to what extent these
findings would apply to other thoracic tumours like the oesophagus. The aim of this study
was to determine if the use of 4D-CT scans in the NeoSCOPE study resulted in any
dosimetric advantage to OARs by using dose volume histogram (DVH) and established NTCP
models to ascertain any potential clinically meaningful toxicity reduction.
Methods
NeoSCOPE Trial
NeoSCOPE was a non-blinded, randomised (1:1 via a centralised computer system), ‘pick a
winner’ phase II trial for patients with resectable oesophageal adenocarcinoma investigating
the benefit of two different nCRT regimens for OC. Surgery was performed 6 to 8 weeks
after nCRT. Primary end-point was pathological complete response (pCR). Secondary end-
points included toxicity, surgical morbidity/mortality, resection rate and overall survival. In
the NeoSCOPE trial, 30-d post-operative respiratory and cardiac complication rates were
36.6%-40% and 9.8%-25.7% respectively. Full trial results have been published elsewhere.[8]
Both arms in the study received 2 cycles of induction chemotherapy with Oxaliplatin
(130mg/m2 day 1) and Capecitabine (625mg/m2 days 1-21). Patients were then randomized
to Oxaliplatin (85mg/m2 IV days 1, 18, 29) and Capecitabine (625mg PO BD on days of
radiotherapy) with radiotherapy or carboplatin (AUC 2) and paclitaxel (50mg/m2 IV on days
1, 8, 15, 22 and 29) with RT. RT consisted of 45Gy in 25 fractions over 5 weeks. Centres
participating in the study could choose to do either 3D or 4D CT planning scans with 4D CT
simulation encouraged for lower oesophagus/GEJ tumours. [8]
Gross tumour volume (GTV) was defined using diagnostic CT scan, endoscopy, EUS and PET
scan (when available). The clinical target volume (CTV) was calculated by growing the GTV
by 2 cm manually along the oesophagus superiorly, inferiorly and 1 cm radially, editing out
lungs and bronchus, heart, liver, aorta and vertebrae. All OARs were defined as per trial
protocol and delineated on a 3D-CT scan that was used for planning and radiotherapy
delivery. A 3D-CT scan was mandated in trial protocol irrespective of whether 4D-CT was
used or not. The planning target volume (PTV) for the 3D cases (PTV3D) was created by
growing CTV 1 cm superiorly and inferiorly and 0.5 cm radially. For 4D cases a PTV4D was
created by growing the internal target volume (ITV) by 0.5cm. [9]
In order to facilitate centres to undertake 4D-CT in the trial, the RT protocol gave two
options for creation of an ITV with 4D-CT (see appendix 1), reflecting the practice of two of
the centres with the most experience in 4D-CT for oesophageal RT at that point in time.
Centres wishing to undertake 4D-CT within the trial were encouraged to attend a workshop
with break-out sessions for both physicists and clinicians, looking at issues surrounding scan
acquisition and outlining respectively. A 4D-CT pre-accrual test case was also made available
for those who were not able to attend the workshop that had to be satisfactorily completed.
Eight centres were approved by the trial to use 4D-CT planning scans for lower third
oesophageal tumours and these eight centres could choose whether to use a 4D-CT
planning scan or not. The data used in this study is made up of 4D-CT planning scans from
Oxford, Leeds and Cardiff. [8]
28/85 (33%) patients recruited to the UK NeoSCOPE trial had a 4DCT scan and 20 (cases
from Oxford, Cardiff, Leeds) of these form the dataset for this study. We had access to 3D-
CT (mandated in NeoSCOPE protocol) and 4D-CT planning scans (optional and not mandated
in the NeoSCOPE trial) along with associated quality-assured structure sets (target volumes
and organs at risk - heart, lungs, spinal cord and liver). A 4D-CT PTV had already been
created by the treating centre, according to the NeoSCOPE 4D-CT protocol. An experienced
clinical oncology trainee also generated a 3D-CT PTV on each of the cases using the 3D-CT
planning scan, according to the NeoSCOPE 3D protocol. These were approved by a
consultant clinical oncologist (SG), who was quality assurance (QA) lead for the NeoSCOPE
trial. As the NeoSCOPE trial protocol required a 3D-CT scan for the radiotherapy planning, it
was possible to use these 3D-CT scans and compare the plans generated with the patients
who also had a 4D-CT plan generated.
Physics Planning
All twenty patients had a 3D conformal plan based on 4D-CT created at the treating centre.
For comparison, we created a 3D conformal plan based on the newly generated 3D-CT PTV.
As NeoSCOPE was a multi-centre trial, the original 4D-CT PTV plans were created using a
range of different linear accelerator machines and treatment planning systems (TPS). To
account for any variation, plans optimised to 3D-CT and 4D-CT PTVs were replanned using
Oncentra MasterPlan (version 4.3) for the purposes of this study. Both sets of plans used
the dose volume constraints set out in the NeoSCOPE protocol (see table 1). 3D conformal
RT was mandated as IMRT was not allowed in NeoSCOPE due to the concerns of pulmonary
toxicity at the time of recruitment. [8]
To ensure consistency with the clinically delivered plan, the same plan parameters approved
as part of the NeoSCOPE trial were used where possible, and then a physicist (AS) adjusted
the plan parameters where necessary (e.g. if the original plan was generated using 5mm
width MLC leaves, some adjustments to MLC segments were required to optimise plan
quality) to optimise the dose distribution (maximising the target coverage whilst minimising
the OAR dose). A similar target conformality was achieved for both plans and the dose
received by the surrounding OARs was assessed. All plans met NeoSCOPE dose constraints.
To ensure plans were clinically acceptable, each plan was reviewed and approved by the
RTTQA lead for the trial. (SG)
Dose reported Constraint
Total PTV volume (ccm) -
PTV (type B algorithm) V95% >99%
ICRU maximum dose D1.8cc <107%




Spinal cord PRV D0.1cc <40Gy
Table 1: Dose objectives specified within the NeoSCOPE trial
The mean differences between the 3D and 4D plans for each of the OAR dose constraints
stated in Table 1 were calculated.
Statistical Analysis
Key metrics related to the two plans were included, including reporting summary measures
such as means, medians and percentiles. Comparisons were reported both in terms of
statistical significance and using more intuitive measures such as the proportion of patients
who would have seen a reduction in risk and the median percentage reduction in exposure.
The distributions of the variables related to the dose constraints were varied and frequently
non-normal. In the interest of consistency and to ensure robust results non-parametric
methods were used to assess statistical significance. More specifically, since each patient
provided matching observations for the two plans (3D and 4D), each constraint was tested
separately using the Wilcoxon Signed Rank test.
In addition, the findings were reported in terms of the reduction in estimated complication
probability.
Normal Tissue Complication Probability (NTCP) Models
In an attempt to assess the clinical significance of the calculated dose volume differences
between the 3D and 4D derived treatment plans, NTCP were calculated for the heart and
the lung volumes within each case. The Lyman-Kutcher-Burman (LKB) model was used to
predict the NTCP for the heart and the lung following radiotherapy treatment, as used often
within the literature. [10, 11]
The LKB model calculates NTCP values for different tissues using the equations and
parameters included in the appendix (see appendix 2). The LKB model descibes the
sigmoidal dose response observed by OARs as an error function. This function is used to
calculate the probability of a specific toxicity end-point occuring, and is dependent upon the
magnitude of the dose incident on the OAR, as well as the proportion of the OARs volume
which is irradiated to that dose level
There are currently no well-validated LKB models for post-operative lung and heart
complications, therefore we selected comparable parameters as surrogates for these
endpoints. A review of the literature led to two sets of LKB parameters being chosen for the
heart and the lungs to attempt to minimise any impact of the LKB model parameters. The
lung models selected assess the probability of inducing grade 2 or grade 3 (or higher)
radiation pneumonitis, and the heart models end points under investigation are pericardial
effusion and radiation induced heart valvular dysfunction. 
Along with the DVH data for the heart and lung exported from the TPS, the model
parameters n, m and d50 were used within the LKB model to generate NTCP data for each
patient.
CERR [12] was used to generate NTCP values using the DVH data and LKB parameters. CERR
is an open source software environment that is based on MATLAB and can be used to
evaluate treatment plans using various parameters.
Results
Plan Statistics
The median volume of the 3D-CT PTVs was 539cm3 compared to 391cm3 for the 4D-CT PTVs
(median difference of 148cm3) giving a percentage reduction in volume of 28% for 4D-CT
PTVs (p= <0.01).
DVH results comparing 3D-CT and 4D-CT plans for the 20 patients are described in Figure 1
and Table 2. 
Figure 1: DVH Results for 3D-CT and 4D-CT plans
Organ Units
Dose
Min Max Median IQR
Spinal cord PRV (3D-CT) cm3 2736 4496 3309 3188-3530
Spinal cord PRV (4D-CT) cm3 2635 4351 3160 2847-3363
Table 2: Dose to Spinal Cord PRV
Comparison of Plans
For each dose constraint a comparison was made between the plans. The results were 
consistent, with the 4D-CT plan resulting in significantly lower dose levels in every case, with
results all significant at the 1% level or below, despite the modest sample size.
The majority of patients would have seen a reduction in the percentage of the OAR 
receiving a given dose. For example, the smallest improvement was observed for spinal cord
PRV of which only 75% of patients would have seen a dose reduction. The expected median 
reduction in this case was 4%. Results were much more notable for the other constraints, 
with 80% of the patients seeing a reduction in the volume of the heart receiving 40Gy. This 
represents a median reduction (IQR) of 23%.
When the entire volume exposed is considered, all patients would have benefitted from 
having a  4D-CT plan, with a 29% reduction in total integral dose. Further details can be 
found in Table 3.
Combined lung (%) 95% 20% 15% - 24% 0.001
Heart V25 (%) 95% 10% 5% - 15% 0.001
Heart V40 (%) 80% 23% 5% - 34% 0.002
Liver V30 (%) 90% 16% 10% - 26% 0.001
Spinal cord PRV (cGy) 75% 4% 0% - 10% 0.005
Volume (ccm) 100% 29% 18% - 37% <0.001




End Point Absolute Reduction
in risk of 4D vs 3D
Relative reduction 
in risk of 4D vs 3D 
Burman et al.[10] Pericarditis/pericardial 
effusion 
0.018% ± 0.001% 33.9% ± 11.6%
Cella et al.[11] Radiation induced heart 
valvular dysfunction
1.9% ± 0.39% 95.0% ± 1.7%
Yorke et al.[13] Lung pneumonitis (>grade 3) 0.056% ± 0.0002% 24.1% ± 8.3%
De Jaeger et al.[14] Lung radiation pneumonitis: 
grade 2, (symptoms requiring 
steroids) or higher
1.005% ± 0.11% 81.1% ± 3.5%
Table 4: Absolute and relative risk reduction of heart and lung toxicity endpoints for 4D-CT and 3D-CT plans
Unsurprisingly, given the significant improvements in dose, the models all reported a 
reduction in risk. However, while the models agreed that there would be a positive benefit  
in terms of NTCP, the magnitude of the effect varies considerably, according to the 
endpoint under investigation.
Although absolute risk reductions are small, the relative risk reductions are significant. The 
relative risk of cardiac toxicity, because of using the 4D plan, is estimated at around 33% for 
pericarditis/pericardial effusion and 95% by radiation induced heart valvular dysfunction. 
Similarly for lung toxicity, the relative risk reduction to the of grade 3 lung pneumonitis is 
24% while for grade 2 toxicity, a figure of 81% is obtained. Further details are found in Table 
4.
In all cases the effect size is large relative to the confidence interval, indicating  a real 
treatment effect is likely to occur and, while there is variation, the magnitude for some 
patients/endpoints  predicting  the potential for meaningful clinical benefit.
Discussion
Our study, which  to the best of our knowledge is the first to study the dosimetric benefit of 
incorporation of 4D-CT into RT for OC, has shown a reduction of dose to heart and lungs 
which  may reduce rates of treatment toxicity. While this study only indicated minimal 
absolute differences in heart and lung complication probability when comparing 3D-CT and 
4D-CT target delineation methods, the significant relative improvements between the two 
techniques suggest the use of a 4D-CT delineation protocol and treatment technique could 
provide a clinically meaningful benefit compared to 3D-CT plans. In addition, there was 
substantial reduction in absolute volume of PTV and integral dose which would facilitate 
further reductions to OARs, even taking into consideration newer techniques such as VMAT 
and proton beam therapy (PBT).
Post-operative Toxicity Reduction
The Esophagectomy Complications Consensus Group (ECCG) recently showed that grade 3-5
cardiac and pulmonary complications occurred in approximately 50% of patients post-
oesophagectomy. The two most common toxicities were pneumonia (14.6%) and atrial
dysrhythmias (14.5%). A significant proportion of patients received nCRT [2].
These rates of severe complications are unacceptably high. In the UK, there remains a
reticence in adopting nCRT for OC compared to other developed countries due in part to the
concern over post-operative toxicities. [3, 4] While perioperative care continues to improve
with the adoption of programmes such as Enhanced Recovery after Surgery (ERAS)[15],
radiation therapy must also adopt new strategies to optimise treatment to minimise toxicity
from neo-adjuvant treatment.
Lung
Wang et al showed that mean lung dose is strongly associated with post-operative
pulmonary complications. [16] Recently published retrospective data comparing 3DRT, IMRT
and PBT showed that post-oesophagectomy lung complications can be reduced by using
techniques that spare dose to lung pre-operatively. [17] Our work has shown 4D-CT will
reduce combined lung dose by around 20% with a probability of grade 3 pneumonitis
reduction of 24.1%. Although there is no randomised control data, we can infer that the use
of 4D-CT may  contribute to a reduction in post-operative lung toxicity.
Heart
Lin et al showed that there was a significantly improved overall survival (OS) and 
locoregional control when IMRT was used to treat patients with OC compared to 3D-CRT, 
with an excess of non-cancer related deaths in the 3D-CRT group compared to IMRT. This 
was postulated to be due to an excess of cardiac related deaths in the 3D-CRT group, likely 
related to the toxic sequelae of thoracic radiotherapy with IMRT resulting in lower cardiac 
doses. These effects were seen within 2 years of CRT. In a separate review of post-
oesophagectomy complications, Lin et al showed that more conformal radiation techniques 
such as IMRT and PBT resulted in significantly less cardiac complications.[17, 18] Mukherjee 
et al demonstrated that a significant dose of radiation during oesophageal chemo 
radiotherapy correlates to a reduction in the cardiac ejection fraction.[19] There is emerging
evidence that a seemingly small dose to specific cardiac substructures such as the sinoatrial 
node can result in a higher incidence of acute arrhythmias. [20] Our work shows a mean 
reduction of heart V40 of 23%, with improvements seen in 80% of the cases. These 
retrospective data clearly support the need of minimising pre-operative dose to the heart to
optimise post-operative and long term outcomes.
Emerging Adjuvant Treatments
The positive findings of the PACIFIC trial of adjuvant immunotherapy (Durvalumab) in lung 
cancer may herald a significant shift in approach to adjuvant therapies post CRT for several 
tumour sites [21]. Early clinical data of adjuvant Durvalumab in OC has shown similar 
promise. [22] The PACIFIC trial reported a pneumonitis rate of 33.9% in the experimental 
arm. [21] This is likely to be a treatment-limiting toxicity for a significant proportion of 
patients. In our study, the use of 4D-CT led to a  relative risk reduction of 81% of grade 2 
pneumonitis and a reduction of 24.1% for grade 3 pneumonitis. Adopting strategies such as 
4D-CT to minimise dose to lung will help ensure the greatest number of patients will be able
to benefit from these emerging treatments.  
Late Toxicity Reduction
OC survival rates for 10 years or more has improved from 4% to 12% in the last 40 years.[1]
The CROSS trial, a study of CRT followed by surgery, demonstrated a median overall survival
of 84.1 months and 48.6 months for patients with squamous and adenocarcinoma of the
oesophagus respectively.[23] As patients live longer following CRT, it becomes increasingly
important to minimise dose in order to limit the long-term side effects causing morbidity
and mortality after treatment. Long term cardiac and pulmonary toxicities following
radiation exposure are well established. Darby et al elegantly demonstrated the risk of
major coronary events is increased by 7.4% per Gy with the effect starting only a few years
after radiation exposure in breast cancer patients. [24] In lung cancer, dose to lung and
heart has been show to clearly impact on long term survival outcomes. [25, 26] Our work
has shown how the incorporation of 4D-CT has a role to play in reducing dose to OARs by
decreasing the high dose region (e.g. V40 Heart) as well as a reduction in integral dose.
Limitations
Despite the trial being multi-centre, numbers of 4D cases were small. This was due to
technical factors such as obtaining complete datasets for our analysis and trial factors as
4DCT was not mandated and was still relatively new to the UK oesophageal RT community
at the time [27]. Additionally, we were unable to access baseline demographic data
including smoking and cardiac history. However, we do not believe this detracts from the
overall findings of this ‘proof of concept’ study, as this was purely a dose distribution and
comparison study, the findings of which are independent of patient demographics.
At the time of the study, concerns regarding lung toxicity led to the decision to avoid
IMRT/VMAT techniques. This study has therefore limited the comparison to 3D-CT and 4D-
CT PTV volume using 3D conformal planning. Increasingly, although not exclusively,
oesophageal radiotherapy is being delivered via IMRT/VMAT. [27] It is unclear if the
magnitude of benefit seen in our study will be maintained when using IMRT/VMAT. Despite
this limitation, this work still shows how absolute PTV volume and integral dose is reduced
using 4D-CT which will undoubtedly give dosimetric advantages irrespective of radiation
technique.
LKB models have historically been widely used but they have been criticised for over-
simplifying dose-volume effects and failing to consider complex biological processes and
interactions thus affecting its predictive power. Increasingly, data-driven logistic regression-
based models are being used and may more accurately predict NTCP, particularly in larger
cohorts of patients. [11, 28] In addition, there is a lack of validated NTCP models looking
specifically at post-oesophagectomy toxicity with several currently in development. [29]
Predicted NTCP values provide a broad indication of toxicity rates for purposes of this study
but caution is needed when translating this into the clinical setting.
Recommendations and Future work
The use of 4D-CT planning scans alongside precision radiotherapy techniques (IMRT and
VMAT) will allow for a further improvement in the therapeutic ratio as both methods allow
for a reduction in post-operative toxicities, late effects and may maximise the potential use
of new adjuvant treatments. 4D-CT allows individualised margins, which are smaller than
the traditional population-based margins, with reduction in dose to the OARs. We believe
that benefits of this study are widely applicable and reproducible as 4D-CT is now broadly
available with a recent survey showing 71% of UK cancer centres now use 4D-CT. [27]
Further work should quantify the magnitude of benefit when using IMRT/VMAT with 4D-CT
compared to 3D-CT planning scans.
Future work should also explore the role of PBT in further reducing the dose to OARs.
Proton’s characteristic Bragg peak allows minimal dose to be deposited to tissues distal to
the target volume. Given the oesophagus’ proximity to organs such as the heart and lung,
PBT has the potential to further improve the therapeutic ratio. Planning studies comparing
modern PBT pencil beam scanning (PBS) technology to precision photon radiotherapy
techniques (IMRT and VMAT) have shown dosimetric advantage of PBT with potential
reduction of lung and heart dose.[30, 31] It is important to note that the use of 4D-CT in PBT
to the thoracic region is already prerequisite in the majority of published literature. [32] This
is due to the sensitivity of PBT dose distribution to intra-fraction motion and tissue
heterogeneity, which necessitates the use of 4D-CT to create robust treatment plans.
In summary, 4D-CT, along with other precision radiotherapy techniques, play a vital role in 
maximising the potential of CRT in oesophageal cancer. We recommend that, where 
possible, all patients undergoing chemo-radiotherapy for potentially curable gastro-
oesophageal junction tumours should receive 4D-CT planning scans to allow a reduction in 
dose to the OARs in order to reduce morbidity associated with treatment and potentially 
improve survival outcomes.
Appendix 1: NeoSCOPE Outlining Protocol
Outlining Protocol for Volume Delineation (as used in the NeoSCOPE Trial):
 The GTV was outlined using diagnostic imaging (CT, PET and EUS) on the 3D scan as
well as the maximum inspiration and expiration phases of the 4D scan. 
 CTV A on the 3D scan was created by manually extending the GTV motion 2cm
proximally and distally (or until the gastro-oesophageal junction). If the superior
extent of the tumour was defined by nodal disease, then the CTV A extension from
the node was 1cm.
 CTV B was formed by CTV A being copied and a 1cm circumferential margin was
added. This was edited for bone, lung, pericardium and the great vessels. For lower
oesophageal tumours, below the GOJ CTV B was extended for 2cm to include the at-
risk lymph nodes regions (lesser curvature of the stomach, left gastric artery and
coeliac region). CTVB 3D was copied and labelled CTVB maximum expiration and CTV
B maximum inspiration. These were edited on the respective sequences as on the 3D
scan. 
 The 3D GTV was combined with the 4D GTVs. There are two methods for this:
1. On the 4D data sets the maximum and minimum phases of motion are identified
as well as the phase that represents the time weighted average (mid phase). On
each phase the GTV, CTVA and CTVB are generated (as detailed below). The ITV
is formed by a composite of CTVB volumes and edited to account for any
additional motion seen from all the other 4DCT phases.
2. Or: the GTV is contoured on the 3D scan. The 4D CT scan is reconstructed on 10
respiratory phases. The inhale and exhale phases are identified (usually between
0 and 50%, respectively). All reconstructions are reviewed to ensure that the
phases represent the extremes. The GTV is contoured in extreme phases and
then the GTV3D GTVMaxIn and GTV MaxEx is combined to give GTV motion. This
volume is checked on all phases of respiration to ensure that all areas are
covered. On the 3D contrast scan create CTVA3D and CTVB3D using the GTV
motion. To obtain the ITV make a copy of CTVB3D and name it CTVBMaxIn and
edit it on the maximum inhale scan. Copy CTVB3D and label it CTVBMaxIn and
edit this on the maximum exhale scan. ITV is formed by combining CTVBMaxIn
and CTVBMaxEx.
 The ITV had a 5mm margin added in all directions to account for set up error, this
was labelled the PTV. 
Appendix 2: LKB model and parameters
Where D represents the Equivalent Uniform Dose (EUD) delivered to the organ (that results
in the same NTCP as the planned non-uniform dose distribution), TD50 is the tolerance dose
to the whole organ which for a given partial volume fraction v, results in a 50% complication
risk, m represents the slope of the NTCP dose-response curve, and n represents the volume
effect of the organ being assessed which can range from 0 to 1. The parameter quantifies
the serial or parallel nature of a given OAR, with smaller values relating to an organ that
exhibits a serial dose response, and larger values reflecting more of a parallel response.




Heart a=6.25,m=0.67,TD=32.8Gy Radiation induced heart
valvular dysfunction
Cella et al[11]
Lung a=1.149,m=0.18,TD=24.5Gy Lung pneumonitis (>grade
3) 
Yorke et al. [13]
Lung a=1,m=0.45,TD=29.2Gy De Jaeger et al [14]
Table 5: LKB Model Parameters
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